This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.

This study has been withdrawn prior to enrollment.
Information provided by:
Hoffmann-La Roche Identifier:
First received: May 23, 2007
Last updated: August 14, 2017
Last verified: August 2017
This single arm study will assess the efficacy of loading doses of intravenous Bondronat in reducing pain in patients with breast cancer and metastatic bone disease experiencing moderate to severe bone pain. Patients will receive an intravenous infusion of 6mg Bondronat on days 1, 2 and 3. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals.

Condition Intervention Phase
Pain Bone Neoplasm Neoplasm Metastasis Drug: ibandronate [Bondronat] Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Study to Assess the Effect of Intravenous Loading Doses of Bondronat on Metastatic Bone Pain in Patients With Breast Cancer and Skeletal Metastases.

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Pain response (20% decrease in mean pain score compared to baseline, and <=50% increase in mean analgesic consumption [ Time Frame: Days 5 - 7 ]

Secondary Outcome Measures:
  • Mean worst pain score over first 7 days [ Time Frame: Day 7 ]
  • Analgesic consumption [ Time Frame: Day 7 ]
  • Karnofsky index [ Time Frame: Day 7 ]
  • AEs, laboratory parameters [ Time Frame: Throughout study ]

Enrollment: 0
Study Start Date: June 2007
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: ibandronate [Bondronat]
6mg iv on days 1-3


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • breast cancer;
  • bone metastases;
  • mean worst pain score >=4 during 3 day baseline period;
  • stable dose of analgesics over a 3 day baseline period;
  • adequate renal function.

Exclusion Criteria:

  • bisphosphonate treatment within 3 weeks of study enrollment;
  • a change in antineoplastic treatment within 6 weeks of study enrollment;
  • bone radiation within 2 weeks of study enrollment;
  • active infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00478270

Alexandroupolis, Greece
Athens, Greece
Haidari, Greece
Patras, Greece
Piraeus, Greece
Thessaloniki, Greece
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Clinical Trials, Study Director, Hoffmann-La Roche Identifier: NCT00478270     History of Changes
Other Study ID Numbers: ML20247
Study First Received: May 23, 2007
Last Updated: August 14, 2017

Additional relevant MeSH terms:
Neoplasm Metastasis
Bone Neoplasms
Neoplastic Processes
Pathologic Processes
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases
Ibandronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on September 21, 2017